Clinical trials: Rectum Carcinoma
Colorectal Cancer, Quality of Life
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00079066
- Testing
- cetuximab, quality-of-life assessment
- Where
- 33 sites in Australia, Canada
- Volunteers
- 572 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Carcinoma, Rectum Carcinoma
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation
Bone marrow is one of the organs at risk of complications during irradiation due to its radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during irradiation of pelvic lymph node areas, especially when…
- Conditions
- Prostate Carcinoma, Rectum Carcinoma, Anal Canal Carcinoma, Endometrium Carcinoma
- Trial name
- MIFADORESOL (NCT04626466)
- Testing
- Biological investigations
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Colon Cancer, Rectal Cancer
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
45 patients undergoing a colon (large bowel/intestine)removal operation for the diagnosis of colon cancer will be included in this study. During colon operation the affected portion of the colon is removed.
- Trial name
- NCT01902953
- Testing
- Lymphoseek and VBD Sln dissection
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Maimonides Medical Center
Gastric Cancer, Non-small Cell Lung Cancer
Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers
Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist.
- Conditions
- Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05800418
- Testing
- Ramucirumab Injection, Ramucirumab Injection [Cyramza]
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rectal Cancer, Non Metastatic Rectal Cancer
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy.
- Trial name
- NCT05629442
- Testing
- ctDNA
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Cancer of Rectum
Early Pelvic Floor Muscle Training Improves Pelvic Floor Muscle Strength in Patient After Low Anterior Resection
The aim of study is to investigate the difference in Maximum Squeeze Pressure in patients with and without pelvic floor muscle training in low anterior resection in peri-operative period
- Trial name
- NCT01146769
- Testing
- Pelvic floor exercise
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Kwong Wah Hospital
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00006479
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 111 sites in Australia, Austria and 11 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005586
- Testing
- L-leucovorin, fluorouracil, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Colorectal Cancer
Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of nitric oxide-releasing acetylsalicyclic acid may prevent colorectal cancer.
- Trial name
- NCT00331786
- Testing
- nitric oxide-releasing acetylsalicylic acid derivative, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Stony Brook University
Colorectal Cancer
Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002570
- Testing
- fluorouracil, leucovorin calcium
- Where
- 16 sites in United States
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Locally Advanced Rectal Cancer (LARC)
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
This is a single-center, open-label, single-arm clinical study aimed at conducting a preliminary evaluation of the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors (dual inhibitors) with neoadjuvant…
- Trial name
- NCT06933251
- Testing
- Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Resectable Rectal Cancer Clinical Stage II and III
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer
A Phase II study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.
- Trial name
- NCT01152710
- Testing
- Capecitabine
- Where
- Slovenia
- Volunteers
- 57 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer
Background: Neoadjuvant chemoradiotherapy (CRT) and total mesorectum excision (TME) has become the standard therapy for the treatment of locally advanced rectal cancer (LARC) to reduce the local recurrence rate, however, no…
- Trial name
- NCT03245203
- Testing
- FOLFIRI+beacizumab, CRT
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Metastatic Colorectal Cancer
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
This is a single-arm, single centre open-label, phase II interventional clinical trial of combination immunotherapy with Nivolumab and Relatlimab in mCRC.
- Trial name
- NCT03867799
- Testing
- Nivolumab
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Rectal Cancer
Rectal Surgery Evaluation Trial (RESET)
Total mesorectal excision (TME) is the standard of care for rectal cancer, which can be combined with low anterior resection (LAR) in patients with mid-to-low rectal cancer.
- Trial name
- RESET (NCT03574493)
- Testing
- TME with LAR
- Where
- France
- Volunteers
- 1,098 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Cancer Surgery
Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery
This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical…
- Trial name
- PREPACOL2 (NCT03491540)
- Testing
- Sennosides colonic preparation, Oral Gentamycin, Oral Ornidazole
- Where
- France
- Volunteers
- 414 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Total Neoadjuvant Treatment, Chemoradiotherapy
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
Purpose:To compare the efficacy and the safety of total neoadjuvant chemotherapy + TME with standard neoadjuvant concurrent chemoradiotherapy + TME + adjuvant chemotherapy for locally advanced rectal cancer patients with high…
- Conditions
- Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer, High Risk Factors
- Trial name
- TNTCRT (NCT03177382)
- Testing
- Total neoadjuvant treatment, concurrent chemoradiotherapy, TME
- Where
- 2 sites in China
- Volunteers
- 458 people
- Sponsor
- West China Hospital
Rectal Adenocarcinoma
GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
A prospective, open, multicenter, randomized III trial with two arms: Arm A: Primary tumor resection , followed by chemotherapy Arm B: Chemotherapy alone.
- Trial name
- GRECCAR8 (NCT02314182)
- Testing
- Primary tumor resection + chemotherapy, Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
- Where
- 3 sites in France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.